Actinium Pharmaceuticals, Inc. (NYSE:ATNM - Get Free Report) rose 7.7% during trading on Tuesday . The company traded as high as $1.84 and last traded at $1.82. Approximately 380,552 shares traded hands during trading, a decline of 28% from the average daily volume of 525,276 shares. The stock had previously closed at $1.69.
Wall Street Analyst Weigh In
ATNM has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, June 24th. Wall Street Zen downgraded shares of Actinium Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $4.00.
Get Our Latest Analysis on ATNM
Actinium Pharmaceuticals Trading Down 1.6%
The stock's 50-day moving average price is $1.61 and its 200-day moving average price is $1.41. The company has a market capitalization of $55.84 million, a P/E ratio of -1.29 and a beta of -0.32.
Institutional Trading of Actinium Pharmaceuticals
Large investors have recently modified their holdings of the company. Callan Family Office LLC acquired a new stake in shares of Actinium Pharmaceuticals in the 1st quarter worth about $38,000. AM Investment Strategies LLC increased its stake in Actinium Pharmaceuticals by 114.1% during the 1st quarter. AM Investment Strategies LLC now owns 30,872 shares of the company's stock valued at $50,000 after buying an additional 16,450 shares during the period. Sei Investments Co. acquired a new position in Actinium Pharmaceuticals during the 4th quarter valued at about $62,000. Bank of America Corp DE increased its stake in Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company's stock valued at $99,000 after buying an additional 34,176 shares during the period. Finally, AQR Capital Management LLC increased its stake in Actinium Pharmaceuticals by 278.6% during the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company's stock valued at $102,000 after buying an additional 46,545 shares during the period. Institutional investors and hedge funds own 27.50% of the company's stock.
About Actinium Pharmaceuticals
(
Get Free Report)
Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
Further Reading
Before you consider Actinium Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actinium Pharmaceuticals wasn't on the list.
While Actinium Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
